Page last updated: 2024-11-13
mms350
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 71519611 |
CHEMBL ID | 4759709 |
SCHEMBL ID | 14880004 |
MeSH ID | M0591604 |
Synonyms (9)
Synonym |
---|
MMS350 |
SCHEMBL14880004 |
3,3'-sulfinylbis(methylene)bis(3-methyloxetane) |
SWJHSMBPLKNKAV-UHFFFAOYSA-N |
1422514-36-0 |
3,3'-(sulfinylbis(methylene))bis(3-methyloxetane) |
STARBLD0002123 |
CHEMBL4759709 |
oxetane, 3,3'-[sulfinylbis(methylene)]bis[3-methyl- |
Research Excerpts
Overview
MMS350 is a non-toxic, highly water-soluble radiation mitigator. It exhibits radioprotective effects on bone marrow stromal cells.
Excerpt | Reference | Relevance |
---|---|---|
"MMS350 is a non-toxic, highly water-soluble radiation mitigator that exhibits radioprotective effects on bone marrow stromal cells." | ( Effects of the bifunctional sulfoxide MMS350, a radiation mitigator, on hematopoiesis in long-term bone marrow cultures and on radioresistance of marrow stromal cell lines. Cao, S; Epperly, MW; Franicola, D; Greenberger, JS; Shields, D; Shinde, A; Sprachman, MM; Wang, H; Wipf, P, ) | 1.12 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (25)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1726133 | Antifibrotic activity in human primary lung fibroblasts assessed as decrease in alpha-SMA protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726146 | Antifibrotic activity against TGFbeta1-induced dermal fibrosis in human skin assessed as reduction in fibronectin expression level stimulated with TGFbeta1 for 24 hrs followed by compound treatment at 500 ug/ml measured after 72 hrs by qRT-PCR analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726153 | Lipophilicity, log P of the compound | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726139 | Antifibrotic activity against bleomycin-induced C57BL/6J mouse lung fibrosis model assessed as reduction in COL1A2 mRNA level at 2%, po via gavage administered as single dose measured within 5 days by qRT-PCR analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726135 | Antifibrotic activity in against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in collagen type-1 protein level at 500 ug/ml treated at 30 mins to 6 hrs post TGFbeta1 stimulation by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726131 | Antifibrotic activity in human primary lung fibroblasts assessed as decrease in IGFBP-3 protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726132 | Antifibrotic activity in human primary lung fibroblasts assessed as decrease in CTGF protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726154 | Solubility of the compound in water | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726136 | Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in IGFBP-3 protein level at 500 ug/ml treated at 30 mins to 6 hrs post TGFbeta1 stimulation by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726138 | Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in alpha-SMA protein level at 500 ug/ml treated at 30 mins to 6 hrs post TGFbeta1 stimulation by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726124 | Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in fibronectin protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726129 | Antifibrotic activity in human primary lung fibroblasts assessed as decrease in fibronectin protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726125 | Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in collagen type-1 protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726130 | Antifibrotic activity in human primary lung fibroblasts assessed as decrease in collagen type-1 protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726140 | Antifibrotic activity against bleomycin-induced C57BL/6J mouse lung fibrosis model at 2%, po via gavage administered as single dose measured after 14 days by hematoxylin and eosin staining based microscopic analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726127 | Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in CTGF protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726128 | Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in alpha-SMA protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726134 | Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in TGFbeta1-induced fibronectin protein level at 500 ug/ml treated at 30 mins to 6 hrs post TGFbeta1 stimulation by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726126 | Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in IGFBP-3 protein level at 500 ug/ml measured after 72 hrs by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726145 | Antifibrotic activity against TGFbeta1-induced dermal fibrosis in human skin assessed as reduction in COL1A1 expression level stimulated with TGFbeta1 for 24 hrs followed by compound treatment at 500 ug/ml measured after 72 hrs by qRT-PCR analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726144 | Antifibrotic activity against TGFbeta1-induced dermal fibrosis in human skin assessed as reduction in CTGF expression level stimulated with TGFbeta1 for 24 hrs followed by compound treatment at 500 ug/ml measured after 24 hrs by QRT-PCR analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726142 | Toxicity in bleomycin-induced C57BL/6J mouse lung fibrosis model assessed as body weight loss | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726137 | Antifibrotic activity against TGFbeta1-induced fibrosis in human primary lung fibroblasts assessed as decrease in CTGF protein level at 500 ug/ml treated at 30 mins to 6 hrs post TGFbeta1 stimulation by immunoblotting analysis | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726143 | Toxicity in bleomycin-induced C57BL/6J mouse lung fibrosis model assessed as improvement in mouse survival relative to control | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
AID1726141 | Antifibrotic activity against bleomycin-induced C57BL/6J mouse lung fibrosis model assessed as reduction in hydroxyproline level in lung at 2%, po via gavage administered as single dose measured on 14 days by hydroxyproline assay | 2020 | ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11 | Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (3)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 29.25
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.25) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |